US House committee opens investigation into Merck, AbbVie China drug trials
Lawmakers seek details on data protection and informed consent after citing more than 100 AbbVie studies in China and 224 Merck studies since 2005.
- On Monday, the China Select Committee opened national security investigations into drugmakers Merck and AbbVie regarding their clinical trial sites in China, seeking details by July 17.
- Lawmakers cite concerns that research at PRC military hospitals exposes American companies to security risks, potentially transferring intellectual property to the Chinese military.
- New Jersey-based Merck has collaborated on 224 studies in China, including at least 31 trials in Xinjiang and 40 at military-affiliated centers.
- Merck asserted that patient safety and ethical integrity remain priorities, while a Chinese embassy spokesperson called the committee's actions "nothing credible."
- By 2024, the U.S. share of early drug development programs fell to around 37% from 48% in 2015, while China's share rose to over 32% from 8%.
18 Articles
18 Articles
U.S. Congress Investigates Security of Clinical Trials in China by Merck, AbbVie, and Others; Biotech Hegemony War Intensifies; 32% of Early-Stage New Drug Clinical Trials in China; Potential for Technology Leakage During Trials; Focus on Chinese Military Hospitals and the Xinjiang Uyghur Region; Regarding the Possibility that Clinical Trials Conducted by Global Pharmaceutical Companies in China Have Been Used to Strengthen China's Military Power
House China Committee Demands Records From 5 US Drugmakers on China Trials
A House committee investigating the Chinese Communist Party (CCP) has demanded records from five major U.S. drugmakers about clinical trials in China that they participated in, citing studies the committee says involved hospitals in Xinjiang and medical sites tied to the Chinese military. Xinjiang has been a focus of U.S. government actions targeting Beijing on human rights and forced labor issues. Rep. John Moolenaar (R-Mich.), chairman of the …
A U.S. congressional committee recently launched an investigation into five prominent pharmaceutical companies, demanding that they explain their past clinical trials conducted in China, particularly those involving Xinjiang and Chinese military hospitals. The committee is concerned that these clinical trials may pose ethical risks and could inadvertently contribute to the development of China's military biotechnology capabilities.
Lawmakers press Eli Lilly for China drug trials tied to military-linked hospitals
Eli Lilly faces a congressional investigation into its China clinical trials at People's Liberation Army hospitals and Xinjiang facilities amid biotechnology competition concerns.
House Committee Opens Investigation Into Merck, AbbVie China Drug Trials
Coverage Details
Bias Distribution
- 59% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
